Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Refine search results

Journals help

  1. 1 OphthaTherapy

Years help

  1. 1 2024

Authors help

  1. 1 Zdzieszyńska M.

Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 1

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Clinical and therapeutic profile of patients with glaucoma treated with latanoprost without macroglycerol-40 hydroxystearate (MGHS-40) - observational study

100%
Zdzieszyńska M.
OphthaTherapy
|
2024
|
vol. 11
|
issue 2
137-145
EN
Purpose: The aim of the study was to evaluate the clinical and therapeutic profile of patients with open-angle glaucoma (OAG) and intraocular hypertension (IHT) who were treated with latanoprost eye drops without macroglycerol-40 hydroxystearate (MGHS-40). Methods: This was a multicenter, open-label, observational, non-interventional study evaluating the clinical and therapeutic profile of patients with glaucoma who received therapy with latanoprost eye drops, without MGHS-40. The study, conducted between April 2022 and July 2023, involved 7171 patients and 270 physician-investigators from across the country. The study included adult patients with OAG and IHT in whom the physician made an independent decision to change therapy or include a drug containing latanoprost without MGHS-40. Results: The results of the study showed that the mean intraocular pressure in this group of patients was 22.6 mmHg. Most of the study participants had a diagnosis of comorbidities – the most common being high blood pressure. Risk factors for OAG were also noted in more than 70% of patients. Predominant among these were a positive family history and smoking. Conclusion: Our study shows that the latanoprost therapy without MGHS-40 is effective in lowering intraocular pressure. The main factors determining a doctor’s decision to use latanoprost without MGHS-40 were good topical tolerability and a simple formulation. The results suggest that this formulation has properties that could enhance patient compliance, possiblyincreasing long-term intraocular pressure-lowering effectiveness.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.